Immunocore, Genentech team up to bring soluble TCR therapy into clinic

Despite losing at least five key executives this year, Immunocore Ltd. (Abingdon, U.K.) has teamed up with Genentech Inc. to advance the first soluble TCR-based therapy from their existing deal into clinical testing for solid tumors.

The partnered therapy, IMC-C103C, will become Immunocore's second compound to enter the clinic since the company raised its high-profile $320 million series A round in 2015, and its third clinical compound overall. Immunocore develops bispecific molecules called ImmTACs which comprise a soluble monoclonal T cell receptor (mTCR) fused to an anti-CD3 immunoglobulin fragment that recruits T cells to the tumor (see "Strengthening the (Immuno)core")...